These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 10698348)

  • 1. Complement activation following oxidative stress.
    Collard CD; Lekowski R; Jordan JE; Agah A; Stahl GL
    Mol Immunol; 1999; 36(13-14):941-8. PubMed ID: 10698348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement activation and inhibition in myocardial ischemia and reperfusion injury.
    Homeister JW; Lucchesi BR
    Annu Rev Pharmacol Toxicol; 1994; 34():17-40. PubMed ID: 8042849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlling the complement system in inflammation.
    Kirschfink M
    Immunopharmacology; 1997 Dec; 38(1-2):51-62. PubMed ID: 9476114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ulex europaeus agglutinin II (UEA-II) is a novel, potent inhibitor of complement activation.
    Lekowski R; Collard CD; Reenstra WR; Stahl GL
    Protein Sci; 2001 Feb; 10(2):277-84. PubMed ID: 11266613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic inhibition of the complement system. Y2K update.
    Asghar SS; Pasch MC
    Front Biosci; 2000 Sep; 5():E63-81. PubMed ID: 10966868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis.
    Weisman HF; Bartow T; Leppo MK; Marsh HC; Carson GR; Concino MF; Boyle MP; Roux KH; Weisfeldt ML; Fearon DT
    Science; 1990 Jul; 249(4965):146-51. PubMed ID: 2371562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement therapeutics; history and current progress.
    Morgan BP; Harris CL
    Mol Immunol; 2003 Sep; 40(2-4):159-70. PubMed ID: 12914822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury.
    Walsh MC; Bourcier T; Takahashi K; Shi L; Busche MN; Rother RP; Solomon SD; Ezekowitz RA; Stahl GL
    J Immunol; 2005 Jul; 175(1):541-6. PubMed ID: 15972690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium.
    Weisman HF; Bartow T; Leppo MK; Boyle MP; Marsh HC; Carson GR; Roux KH; Weisfeldt ML; Fearon DT
    Trans Assoc Am Physicians; 1990; 103():64-72. PubMed ID: 2132543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble complement receptor type 1 inhibits the complement pathway and prevents contractile failure in the postischemic heart. Evidence that complement activation is required for neutrophil-mediated reperfusion injury.
    Shandelya SM; Kuppusamy P; Herskowitz A; Weisfeldt ML; Zweier JL
    Circulation; 1993 Dec; 88(6):2812-26. PubMed ID: 8252695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C1-esterase inhibitor in ischemia and reperfusion.
    Horstick G
    Immunobiology; 2002 Sep; 205(4-5):552-62. PubMed ID: 12396015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of complement inhibitors in myocardial ischaemia.
    Lucchesi BR; Tanhehco EJ
    Expert Opin Investig Drugs; 2000 May; 9(5):975-91. PubMed ID: 11060721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initiation of complement activation following oxidative stress. In vitro and in vivo observations.
    Hart ML; Walsh MC; Stahl GL
    Mol Immunol; 2004 Jun; 41(2-3):165-71. PubMed ID: 15159062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The complement system in myocardial ischaemia/reperfusion injury.
    Kilgore KS; Friedrichs GS; Homeister JW; Lucchesi BR
    Cardiovasc Res; 1994 Apr; 28(4):437-44. PubMed ID: 8181029
    [No Abstract]   [Full Text] [Related]  

  • 15. Endothelial targeting and enhanced antiinflammatory effects of complement inhibitors possessing sialyl Lewisx moieties.
    Mulligan MS; Warner RL; Rittershaus CW; Thomas LJ; Ryan US; Foreman KE; Crouch LD; Till GO; Ward PA
    J Immunol; 1999 Apr; 162(8):4952-9. PubMed ID: 10202042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble complement receptor one (sCR1) inhibits the development and progression of rat collagen-induced arthritis.
    Goodfellow RM; Williams AS; Levin JL; Williams BD; Morgan BP
    Clin Exp Immunol; 2000 Jan; 119(1):210-6. PubMed ID: 10606985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A keratin peptide inhibits mannose-binding lectin.
    Montalto MC; Collard CD; Buras JA; Reenstra WR; McClaine R; Gies DR; Rother RP; Stahl GL
    J Immunol; 2001 Mar; 166(6):4148-53. PubMed ID: 11238665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement and its implications in cardiac ischemia/reperfusion: strategies to inhibit complement.
    Monsinjon T; Richard V; Fontaine M
    Fundam Clin Pharmacol; 2001 Oct; 15(5):293-306. PubMed ID: 11903498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of cardiac cell injury during acute myocardial infarction: possible role for complement inhibition.
    de Zwaan C; van Dieijen-Visser MP; Hermens WT
    Am J Cardiovasc Drugs; 2003; 3(4):245-51. PubMed ID: 14728077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of complement inhibitors in tissue injury.
    Quigg RJ
    Trends Mol Med; 2002 Sep; 8(9):430-6. PubMed ID: 12223314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.